A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer-Reference-Cited by-同舟云学术

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

Published:2020-08 Issue:6 Volume:13 Page:1178-1188
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Murphy Adrian G.¹,Zahurak Marianna²,Shah Mirat¹,Weekes Colin D.³,Hansen Aaron⁴,Siu Lillian L.⁴,Spreafico Anna⁴,LoConte Noelle⁵,Anders Nicole M.¹⁶,Miles Tearra¹,Rudek Michelle A.¹⁶⁷,Doyle L. Austin⁸,Nelkin Barry¹,Maitra Anirban¹,Azad Nilofer S.¹,

Affiliation:

1. Department of Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore Maryland USA

2. Department of Oncology Biostatistics Johns Hopkins University School of Medicine Baltimore Maryland USA

3. University of Colorado Boulder Colorado USA

4. Division of Medical Oncology and Haematology Princess Margaret Cancer Centre Toronto Ontario Canada

5. University of Wisconsin Carbone Cancer Center Madison Wisconsin USA

6. Analytical Pharmacology Core Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Baltimore Maryland USA

7. Division of Clinical Pharmacology Department of Medicine School of Medicine Johns Hopkins University Baltimore Maryland USA

8. Cancer Therapy Evaluation Program National Cancer Institute Bethesda Maryland USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12802

Reference52 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration

3. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992–2013

4. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

5. Integrated genomic and molecular characterization of cervical cancer

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The trend toward more target therapy in pancreatic ductal adenocarcinoma;Expert Review of Anticancer Therapy;2024-05-23

2. The signalling axis CDK12-BRCA1 mediates dinaciclib associated radiosensitivity through p53-mediated cellular senescence;2024-04-28

3. Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023);Expert Opinion on Therapeutic Patents;2024-03-03

4. Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer;International Journal of Molecular Sciences;2024-03-01

5. Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression;Cancer Research;2024-02-08